NANO Nanobiotix SA

NANOBIOTIX to Present at the Jefferies London Healthcare Conference

NANOBIOTIX to Present at the Jefferies London Healthcare Conference

PARIS and Cambridge, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a fireside chat at the Jefferies London Healthcare Conference at 5:00 PM GMT/12:00 PM ET on Tuesday, November 15, 2022.

The fireside chat will be webcast live from the of the Investors section of the Company’s website. A replay of the webcast will be archived and available for at least 30 days following the event.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at or follow us on and .

Contacts

Nanobiotix 


Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835







Investor Relations Department

Kate McNeil

SVP, Investor Relations

+1 (609) 678-7388





 
Media Relations 
FR – Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51



Global – LifeSci Advisors

Ligia Vela-Reid

+44 (0) 7413825310

 





EN
31/10/2022

Underlying

NANONanobiotix SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Nanobiotix Provides First Quarter 2025 Operational and Financial Updat...

Nanobiotix Provides First Quarter 2025 Operational and Financial Update Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage 3 unresectable non-small cell lung cancerPresentation of data at the European Lung Cancer Conference in a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) in locoregional recurrent NSCLC and a Phase 1 study of JNJ-1900 (NBTXR3) in combination with nivolumab or pembrolizumab for patients with lung metastases from NSCLC or other solid tumorsStrengthened financial position through an amendment to th...

May 21, 2025 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Nanobiotix fait le point sur sa trésorerie et son activité opérationne...

Nanobiotix fait le point sur sa trésorerie et son activité opérationnelle du premier trimestre 2025 Traitement du premier patient dans l’étude CONVERGE, un essai clinique contrôlé randomisé de Phase 2 chez des patients atteints d’un cancer du poumon non à petites cellules (CPNPC) non résécable de stade 3.Présentation de données à l’ELCC (European Lung Cancer Conference, conférence européenne sur le cancer du poumon) d’une étude de Phase 1 de ré-irradiation avec JNJ-1900 (NBTXR3) dans le CPNPC récurrent locorégional et une étude de Phase 1 avec JNJ-1900 (NBTXR3) en association avec nivoluma...

May 21, 2025 1 EN
Free Trial
NANO NANOBIOTIX SA

Nanobiotix: 1 director

A director at Nanobiotix bought 10,000 shares at 2.900EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

05/16/25 May 16, 2025 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, May 14, 2025 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights,exercisable2April 30, 202547,426,85149,535,88349,513,765 About NANOBI...

May 14, 2025 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’...

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 14 mai 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / NasdaqEuronext Compartiment : B Code ISIN : FR0011341205Nasdaq : NBTXBloomberg : NANO:FPReuters : NANO.PASite web : DateNombre total d’actions composant le capital socialNombre total de droits de voteTotal théorique1Total exerçable230 avril 202547 426 85149 535 88349 513 765 À prop...

May 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch